Prescribing preferences of U.S. oncologists for patients (Pts) with metastatic urothelial carcinoma (mUC) at first recurrence: Impact of novel agents.

365 Background: In May 2016 atezolizumab (A) was approved for the treatment of pts with locally advanced or mUC who have disease progression during or following platinum-containing chemotherapy (PCCT), or within 12 months (mos) of neoadjuvant or adjuvant treatment with PCCT. We evaluated prescribing preferences (PPrefs) of 248 U.S-based oncologists for 1strecurrence treatment across a range of clinical scenarios prior to and following A approval. Methods: PPrefs were assessed through a validated, case-based market research tool (Challenging Cases). Assessment dates were 3/5 and 4/30 (PRE-) and 8/6 (POST-approval). Data were acquired using blinded, audience-response technology. A core scenario (CS) and 5 variant scenarios (V1, 2, 3, 4, 5) were utilized. CS: 69-year-old pt with muscle invasive bladder cancer, with a CrCl 62 ml/min, Hgb 12.5, and PS 1, recurs in the liver and bone 18 months after receiving neoadjuvant gemcitabine/cisplatin and a radical cystectomy. V1: Same as CS but with reduced CrCl 48 ml/min. V2: Same as CS but recurrence at 6 months. V3: Same as V2 but multiple comorbidities and PS 2. V4: Same as CS but age 79. V5: Same as V4 but multiple comorbidities. The same query was posed in each setting: What therapy would you choose? Results: See Table. Conclusions: Following the approval of A, overall PPref of most regimens offered decreased across nearly all 1st recurrence scenarios in favor of A. This is particularly stark in platinum unfit (older, comorbid, poor PS) pts. This highlights the previously unmet medical need in the PCCT pre-treated mUC pts. [Table: see text]

First-Line Prescribing Preferences of U.S. Hematology-Oncology Physicians for Patients with CLL: Impact of Novel Agents

Background: In November, 2013 obinutuzumab (obin) was approved in combination with chlorambucil (chlor), as 1st line therapy (Rx) for patients (pts) with chronic lymphocytic leukemia (CLL). In February, 2014, ibrutinib was approved in CLL for pts who had received > 1 prior therapy. In April, 2014 ofatumumab (ofa) + chlor was approved as 1st line Rx for pts with CLL for whom fludarabine-based therapy is considered inappropriate. During 2014 we studied PPrefs of 180 U.S-based hematology-oncology physicians (HOPs) for 1stline Rx across a range of clinical scenarios varying by age, co-morbidities, and selected laboratory features. Methods: PPrefs were assessed through a validated, proprietary, live, case-based market research tool (Challenging Cases®). Assessment dates were 3/08/14 and 4/26/14. Data were acquired using blinded, audience-response technology. A core scenario (CS) and 3 variant scenarios (VS) were utilized to evoke physician PPrefs. CS: 63-year-old male; 1-2 cm diffuse adenopathy, spleen 3 cm below costal margin. Presented with recent fatigue/ low grade fevers; no relevant co-morbidities; CD 38=12%. No FISH abnormalities. PS1. VS1: All equal except 17p deletion and CD 38 = 42%; VS2: CS (age 63; no abnormal FISH) plus co-morbidities (medication-controlled hypertension, type II diabetes, and mild COPD); VS3: VS2 BUT age 73 with same co-morbidities. Results: PPrefs by scenario shown below: Abstract 4676. Table 1PPref CS VS1 VS2 VS33/8/144/26/143/8/144/26/143/8/144/26/143/8/144/26/14Bendamustine + rituximab[BR]61%63%52%51%72%68%66%64%Bendamustine + Obinutuzumab0%2%2%6%0%1%3%2%Chorambucil + Obinutuzumab1%3%2%3%2%5%8%17%FCR20%16%25%19%5%8%1%2%Ibrutinib + additional agent(s)2%3%11%16%7%8%6%7%Other2%2%4%2%2%2%3%2%Observe14%10%3%3%11%6%12%5% Conclusions: As of March-April 2014 BR is the 1st line PPref of 51% -72% of US-based HOPs across 4 plausible newly diagnosed CLL scenarios. In VS1 (age 63; 17p deletion) ibrutinib based Rx is emerging despite lack of 1st line indication. In VS 3 (age 73, multiple co-morbidities present, neither high risk FISH nor CD 38 positivity) 1st line PPref for Chlor + Obin is emerging. Prior to ASH 2014, we will assess PPrefs of approximately 180 additional HOPs related to these scenarios (with ofatumumab + chlorambucil added as a treatment option) and have aggregate PPref data (N > 350) across all of 2014 for ASH. Disclosures Williams: Pharmacyclics, Janssen: Consultancy, Research Funding.

Computers, Survey Research, and Focus Groups in Public Administration Research and Practice

The integration of computing into survey research and focus groups in research and practice in public administration and related fields is the focus of this chapter. Coverage applies to other social science disciplines as well. This chapter reviews uses of computers in computer-assisted survey research (CASR), computer-assisted interviewing, computer-assisted telephone interviewing (CATI), computerassisted personal interviewing (CAPI), and transferring survey research methods onto the Internet. A second portion of the chapter gives special attention to continuous audience response technology (CART). An example of a citizen survey focused on growth issues combined with a focus group dealing with the same topic in Cary, North Carolina, is also provided. <BR>